Methods of treating cancer using neurotrophin retargeted endopeptidases

Details for Australian Patent Application No. 2010282276 (hide)

Owner Allergan, Inc.

Inventors Jacky, Birgitte P.S.; Garay, Patton E.; Molina, Yanira; Stathakis, Dean G.; Francis, Joseph; Aoki, Kei Roger; Fernandez-Salas, Ester; Steward, Lance E.; Ghanshani, Sanjiv; Hunt, Terrence J.

Agent Davies Collison Cave

Pub. Number AU-A-2010282276

PCT Pub. Number WO2011/020117

Priority 61/233,969 14.08.09 US

Filing date 16 August 2010

Wipo publication date 17 February 2011

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

15 March 2012 PCT application entered the National Phase

  PCT publication WO2011/020117 Priority application(s): WO2011/020117

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010282278-Methods of treating cancer using glucagon-like hormone retargeted endopeptidases

2010282274-Methods of treating cancer using growth factor retargeted endopeptidases